Revance Therapeutics (RVNC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 12-2015 | 09-2015 | 06-2015 | 03-2015 | 12-2014 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -73,476 | -51,382 | -32,207 | -15,402 | -62,917 |
| Depreciation Amortization | 2,596 | 1,994 | 1,247 | 575 | 3,504 |
| Accounts payable and accrued liabilities | -692 | -477 | -938 | -1,195 | -3,399 |
| Other Working Capital | 2,524 | 2,661 | 642 | -569 | -10,232 |
| Other Operating Activity | 13,379 | 7,986 | 5,744 | 3,565 | 17,971 |
| Operating Cash Flow | $-55,669 | $-39,218 | $-25,512 | $-13,026 | $-55,073 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -3,328 | -2,849 | -2,292 | -1,801 | -6,975 |
| Purchase Of Investment | -54,087 | -54,087 | -53,076 | N/A | N/A |
| Sale Of Investment | 1,000 | N/A | N/A | N/A | N/A |
| Other Investing Activity | 0 | 75 | 75 | 75 | 0 |
| Investing Cash Flow | $-56,415 | $-56,861 | $-55,293 | $-1,726 | $-6,975 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | N/A | N/A | N/A | N/A | 6,750 |
| Debt Repayment | -5,250 | -4,420 | -3,608 | -2,736 | -12,544 |
| Common Stock Issued | 139,004 | 10,892 | 587 | 173 | 236,323 |
| Other Financing Activity | 8,838 | 9,069 | 9,211 | 0 | -1,438 |
| Financing Cash Flow | $142,592 | $15,541 | $6,190 | $-2,563 | $229,091 |
| Beginning Cash Position | 171,542 | 171,032 | 171,032 | 171,032 | 4,499 |
| End Cash Position | 202,050 | 90,494 | 96,417 | 153,717 | 171,542 |
| Net Cash Flow | $30,508 | $-80,538 | $-74,615 | $-17,315 | $167,043 |
| Free Cash Flow | |||||
| Operating Cash Flow | -55,669 | -39,218 | -25,512 | -13,026 | -55,073 |
| Capital Expenditure | -3,328 | -2,849 | -2,292 | -1,801 | -6,975 |
| Free Cash Flow | -58,997 | -42,067 | -27,804 | -14,827 | -62,048 |